Åpne denne publikasjonen i ny fane eller vindu >>Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden..
Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Neurosurg, Solna, Sweden..
Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway.;Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway..
Univ Hosp Northern Sweden, Dept Neurosurg, Umeå, Sweden.;Umeå Univ, Dept Clin Sci, Neurosci, Umeå, Sweden..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Neurokirurgi.
Univ Bergen, Fac Med, Dept Clin Med, Bergen, Norway.;Haukeland Hosp, Dept Neurosurg, Bergen, Norway..
Linköping Univ Hosp, Dept Neurosurg, Linköping, Sweden.;Linköping Univ, Dept Biomed & Clin Sci, Jönköping, Sweden..
Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden..
Skane Univ Hosp, Dept Clin Sci, Lund, Sweden.;Skane Univ Hosp, Dept Neurosurg, Skane, Sweden..
Univ Hosp North Norway, Dept Neurosurg, Tromso, Sweden..
Univ Hosp Northern Sweden, Dept Neurosurg, Umeå, Sweden.;Umeå Univ, Dept Clin Sci, Neurosci, Umeå, Sweden..
Linköping Univ Hosp, Dept Neurosurg, Linköping, Sweden.;Linköping Univ, Dept Biomed & Clin Sci, Jönköping, Sweden..
Skane Univ Hosp, Dept Neurosurg, Skane, Sweden..
Univ Bergen, Fac Med, Dept Clin Med, Bergen, Norway.;Haukeland Hosp, Dept Neurosurg, Bergen, Norway..
Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Neurokirurgi.
Karolinska Univ Hosp, Dept Neurosurg, Solna, Sweden.;Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden.;Copenhagen Univ Hosp, Rigshospitalet, Dept Neurosurg, Copenhagen, Denmark..
Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway.;Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden..
Vise andre…
2025 (engelsk)Inngår i: Frontiers in Oncology, E-ISSN 2234-943X, Vol. 15, artikkel-id 1703756Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Background and objectives Maximal safe resection is the cornerstone of diffuse low-grade glioma (dLGG) management, although epidemiological data are limited. We aim to explore surgical selection, techniques, and outcomes in a population-based cohort.Materials and methods This study utilized a multi-center case series (9 out of 10 neurosurgical departments in Norway and Sweden) of all adults (>= 18 years) with histopathologically verified supratentorial dLGG, WHO grade 2, undergoing primary surgery from 2012-2017. Complications within 30 days and neurological outcomes at 3 months were assessed. Pre- and postoperative MRIs were reviewed centrally, blinded to patient outcome and center.Results Of 517 included patients, 217 (41.7%) were female, and the mean (SD) age was 44.5 (15.0) years. Biopsy only was performed in 119 (23.0%) patients (13.8-38.9% across centers), and 398 (77.0%) underwent resection (61.1-86.2%). Intraoperative neurophysiological monitoring (IONM) was used in 142 (35.7%, 0-58.7%) resections. The biopsy-only patients were older (52.7 years vs. 42.1 years, P<.001), had larger tumors (56.6 ml vs. 31.9 ml, P<.001), and these tumors were more often eloquently located (86.6% vs. 56.5%, P<.001). The median (IQR) extent of resection (EOR) was 82.9% (63.3-97.7%), 69.7-100.0% across centers. The median (IQR) residual tumor was 4.6 ml (0.5-19.9 ml), 0.0-14.1 ml across centers. Age and histopathology were the most important predictors of EOR. New/worsened neurological deficits occurred in 165 patients (41.5%), 23.1-66.7% across centers, and persisted in 19 (4.8%, 0-22.7%) at 3 months after surgery. A complication was observed in 87 patients (21.4%, 0-31.7%), with 12 patients (3.1%, 0-9.8%) having grade III-IV complications.Conclusions We found that surgical selection was associated with age, tumor size, and location. The median EOR in a population-based cohort was 83%, with age and tumor biology being significant predictors. EOR did not correlate with higher risks or worse neurological outcomes. We provide an epidemiological perspective demonstrating a variation in surgical selection and techniques reflecting persistent controversy in dLGG management.
sted, utgiver, år, opplag, sider
Frontiers Media S.A., 2025
Emneord
extent of resection, glioma, low-grade glioma, neurological deficits, neurosurgery, oncology, surgical outcomes
HSV kategori
Identifikatorer
urn:nbn:se:uu:diva-575544 (URN)10.3389/fonc.2025.1703756 (DOI)001636528100001 ()41395619 (PubMedID)2-s2.0-105025055762 (Scopus ID)
2026-01-142026-01-142026-01-14bibliografisk kontrollert